Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/prp2.631 http://scihub22266oqcxt.onion/10.1002/prp2.631 32715661!7383088!32715661     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacol+Res+Perspect 2020 ; 8 (4): e00631 Nephropedia Template TP {{tp|p=32715661|t=2020. Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients |pdf=|usr=}}{{32715661}} gab.com Text Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients JO: Pharmacol Res Perspect http://www.kidney.de/pget.php?&tw=1&pmid=32715661 #FOAvip We propose a new hypothesis that the established drug pentoxifylline deserves attention as a potential repurposed therapeutic for COVID-19. Pentoxifylline is an immunomodulator with anti-inflammatory properties. It is a nonselective phosphodiesterase inhibitor and through Adenosine A2A Receptor-mediated pathways reduces tumor necrosis factor alpha, interleukin 1, interleukin 6, and interferon gamma and may act to reduce tissue damage during the cytokine storm host response to SARS-CoV-2 infection. This agent has been used clinically for many years and has a favorable profile of safety and tolerability. Pre-clinical data support pentoxifylline as effective in cytokine-driven lung damage. Clinical studies of pentoxifylline in radiation and cytokine-induced lung damage in humans are positive and consistent with anti-inflammatory efficacy. Pentoxifylline is a readily available, off-patent and inexpensive drug, suitable for large-scale use including in resource-limited countries. Current trials of therapeutics are largely focused on the inhibition of viral processes. We advocate urgent randomized trials of pentoxifylline for COVID-19 as a complementary approach to target the host responses. Twit Text FOAVip Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients ????Pharmacol Res Perspect http://www.kidney.de/pget.php?&tw=1&pmid=32715661 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32715661 #FOAvip English Wikipedia <ref>{{Cite pmid|32715661}}</ref> Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients #MMPMID32715661 Hendry BM; Stafford N; Arnold AD; Sangwaiya A; Manglam V; Rosen SD; Arnold J Pharmacol Res Perspect 2020[Aug]; 8 (4): e00631 PMID32715661show ga We propose a new hypothesis that the established drug pentoxifylline deserves attention as a potential repurposed therapeutic for COVID-19. Pentoxifylline is an immunomodulator with anti-inflammatory properties. It is a nonselective phosphodiesterase inhibitor and through Adenosine A2A Receptor-mediated pathways reduces tumor necrosis factor alpha, interleukin 1, interleukin 6, and interferon gamma and may act to reduce tissue damage during the cytokine storm host response to SARS-CoV-2 infection. This agent has been used clinically for many years and has a favorable profile of safety and tolerability. Pre-clinical data support pentoxifylline as effective in cytokine-driven lung damage. Clinical studies of pentoxifylline in radiation and cytokine-induced lung damage in humans are positive and consistent with anti-inflammatory efficacy. Pentoxifylline is a readily available, off-patent and inexpensive drug, suitable for large-scale use including in resource-limited countries. Current trials of therapeutics are largely focused on the inhibition of viral processes. We advocate urgent randomized trials of pentoxifylline for COVID-19 as a complementary approach to target the host responses. |*Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy[MESH] |Humans[MESH] |Pandemics[MESH] |Pentoxifylline/pharmacology/*therapeutic use[MESH] |Phosphodiesterase Inhibitors/*therapeutic use[MESH] |Pneumonia, Viral/*drug therapy[MESH] |Research Design[MESH] |SARS-CoV-2[MESH]Hypothesis: Pentoxifylline is a potential cytokine modulator therapeut(epmc).pdf DeepDyve Pubget Overpricing